Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

neocannbio.com

Founded Year

2021

Stage

Series A | Alive

Total Raised

$3.43M

Last Raised

$3.43M | 2 mos ago

About Neocannbio

Neocannbio develops and discovers drugs using cannabinoid ingredients. The company is developing a GMP production process for high-purity cannabidiol (CBD) using microwave processing technology, enabling the mass production of cannabinoids in a safe and efficient manner. Neocannbio was founded in 2021 and is based in Seoul, South Korea.

Neocannbio Headquarters Location

KIST, H-1, 952B 5, Hwarang-ro 14-gil, Seongbuk-gu

Seoul, 02792,

South Korea

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

  • When was Neocannbio founded?

    Neocannbio was founded in 2021.

  • Where is Neocannbio's headquarters?

    Neocannbio's headquarters is located at KIST, H-1, 952B, Seoul.

  • What is Neocannbio's latest funding round?

    Neocannbio's latest funding round is Series A.

  • How much did Neocannbio raise?

    Neocannbio raised a total of $3.43M.

  • Who are the investors of Neocannbio?

    Investors of Neocannbio include Medytox Venture, HLB, KT&G, HLB Investment, Hyundai Venture Investment Corporation and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.